Hualan Biological Engineering Inc. (SHE:002007)
14.98
+0.04 (0.27%)
Apr 15, 2026, 10:15 AM CST
SHE:002007 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 4,584 | 4,366 | 5,333 | 4,503 | 4,426 |
Other Revenue | 10.93 | 13.58 | 8.9 | 13.67 | 10.31 |
| 4,595 | 4,379 | 5,342 | 4,517 | 4,436 | |
Revenue Growth (YoY) | 4.93% | -18.02% | 18.26% | 1.82% | -11.69% |
Cost of Revenue | 2,013 | 1,768 | 1,727 | 1,699 | 1,538 |
Gross Profit | 2,582 | 2,611 | 3,615 | 2,818 | 2,898 |
Selling, General & Admin | 1,040 | 1,066 | 1,465 | 1,205 | 1,011 |
Research & Development | 337.46 | 333.18 | 280.84 | 314.7 | 253.63 |
Other Operating Expenses | 41.46 | 38.35 | 44.62 | 41.75 | 36.17 |
Operating Expenses | 1,453 | 1,432 | 1,805 | 1,595 | 1,312 |
Operating Income | 1,130 | 1,179 | 1,810 | 1,223 | 1,586 |
Interest Expense | -10.24 | -12.95 | -13.17 | -30.27 | -21.72 |
Interest & Investment Income | 72.59 | 157.95 | 164.47 | 128.92 | 85.28 |
Currency Exchange Gain (Loss) | 0.25 | -0.15 | -0.3 | -0.01 | 0.33 |
Other Non Operating Income (Expenses) | -0.55 | -0.49 | -0.28 | -0.38 | -0.34 |
EBT Excluding Unusual Items | 1,192 | 1,323 | 1,961 | 1,322 | 1,650 |
Gain (Loss) on Sale of Investments | 15.17 | 32.94 | 60.54 | 36.11 | 26.86 |
Gain (Loss) on Sale of Assets | 2.89 | 0.08 | 44.44 | 47.67 | 0.42 |
Asset Writedown | -3.53 | -5.71 | -9.71 | -1.19 | -3.23 |
Other Unusual Items | -32.77 | -11.81 | 21.24 | 24.17 | 14.39 |
Pretax Income | 1,173 | 1,339 | 2,078 | 1,428 | 1,688 |
Income Tax Expense | 173.36 | 183.14 | 315.96 | 180.76 | 234.13 |
Earnings From Continuing Operations | 999.99 | 1,155 | 1,762 | 1,248 | 1,454 |
Minority Interest in Earnings | -59.59 | -67.62 | -280.11 | -171.34 | -155.22 |
Net Income | 940.4 | 1,088 | 1,482 | 1,076 | 1,299 |
Net Income to Common | 940.4 | 1,088 | 1,482 | 1,076 | 1,299 |
Net Income Growth | -13.55% | -26.57% | 37.66% | -17.14% | -19.48% |
Shares Outstanding (Basic) | 1,826 | 1,826 | 1,824 | 1,825 | 1,821 |
Shares Outstanding (Diluted) | 1,826 | 1,829 | 1,824 | 1,828 | 1,831 |
Shares Change (YoY) | -0.16% | 0.23% | -0.19% | -0.17% | 0.59% |
EPS (Basic) | 0.52 | 0.60 | 0.81 | 0.59 | 0.71 |
EPS (Diluted) | 0.52 | 0.59 | 0.81 | 0.59 | 0.71 |
EPS Growth | -13.41% | -26.75% | 37.92% | -17.00% | -19.95% |
Free Cash Flow | 680.65 | 803.92 | 592.43 | 563.36 | 621.15 |
Free Cash Flow Per Share | 0.37 | 0.44 | 0.33 | 0.31 | 0.34 |
Dividend Per Share | 1.000 | 0.200 | 0.300 | 0.300 | 0.200 |
Dividend Growth | 400.00% | -33.33% | - | 50.00% | -33.33% |
Gross Margin | 56.19% | 59.62% | 67.67% | 62.38% | 65.33% |
Operating Margin | 24.58% | 26.92% | 33.89% | 27.08% | 35.76% |
Profit Margin | 20.47% | 24.84% | 27.73% | 23.83% | 29.28% |
Free Cash Flow Margin | 14.81% | 18.36% | 11.09% | 12.47% | 14.00% |
EBITDA | 1,403 | 1,439 | 2,069 | 1,496 | 1,783 |
EBITDA Margin | 30.54% | 32.87% | 38.74% | 33.12% | 40.18% |
D&A For EBITDA | 273.88 | 260.46 | 259.05 | 272.5 | 196.39 |
EBIT | 1,130 | 1,179 | 1,810 | 1,223 | 1,586 |
EBIT Margin | 24.58% | 26.92% | 33.89% | 27.08% | 35.76% |
Effective Tax Rate | 14.77% | 13.68% | 15.21% | 12.65% | 13.87% |
Revenue as Reported | 4,595 | 4,379 | 5,342 | 4,517 | 4,436 |
Advertising Expenses | 5.42 | 5.08 | 6.31 | 2.84 | 3.38 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.